Onsdag 30 Oktober | 09:27:10 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

Tid*
2024-11-01 07:00 Kvartalsrapport 2024-Q3
2024-09-09 - X-dag ordinarie utdelning AKBM 45.00 NOK
2024-09-03 - Extra Bolagsstämma 2024
2024-07-12 - Kvartalsrapport 2024-Q2
2024-04-26 - Kvartalsrapport 2024-Q1
2024-04-17 - X-dag ordinarie utdelning AKBM 0.00 NOK
2024-04-16 - Årsstämma
2024-02-14 - Bokslutskommuniké 2023
2023-11-01 - Kvartalsrapport 2023-Q3
2023-07-14 - Kvartalsrapport 2023-Q2
2023-04-28 - Kvartalsrapport 2023-Q1
2023-04-21 - X-dag ordinarie utdelning AKBM 0.00 NOK
2023-04-20 - Årsstämma
2023-02-15 - Bokslutskommuniké 2022
2022-11-01 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-04-29 - Kvartalsrapport 2022-Q1
2022-04-21 - X-dag ordinarie utdelning AKBM 0.00 NOK
2022-04-20 - Årsstämma
2022-02-17 - Bokslutskommuniké 2021
2021-10-29 - Kvartalsrapport 2021-Q3
2021-07-14 - Kvartalsrapport 2021-Q2
2021-04-29 - Kvartalsrapport 2021-Q1
2021-03-15 - X-dag ordinarie utdelning AKBM 0.00 NOK
2021-03-12 - Årsstämma
2021-02-16 - Bokslutskommuniké 2020
2020-10-30 - Kvartalsrapport 2020-Q3
2020-07-15 - Kvartalsrapport 2020-Q2

Beskrivning

LandNorge
ListaOB Match
SektorHandel & varor
IndustriDagligvaror
Aker BioMarine är verksamma inom bioteknik. Bolaget är specialiserade inom utveckling av kostillskott. Produktportföljen är bred och inkluderar exempelvis omega-3 olja, näringstillskott för djur, samt proteintillskott för fiskeodling. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Kunderna består av både privata aktörer samt grossister. Aker BioMarine grundades år 2006 och har sitt huvudkontor i Oslo.
2023-12-08 12:47:43
8 December 2023: Aker BioMarine has received purchase orders of USD 6.0 million
for Algae based Omega-3 Oils (for human consumption) with a gross margin similar
to Superba. Delivery will be throughout 2024. The Algae Oil will be produced in
the company's factory in Houston, where we have built a dedicated production
line which is on stream.

"This is a great example of how we can use the skills and expertise in our
Houston production facility as a platform to grow into new product lines. We
have great synergies from both our existing equipment and teams, which enables
expansion into algae oil with limited additional costs. The move into algae oil
is exciting, especially given the current pressure on fish oil prices.", said
Matts Johansen, CEO of Aker BioMarine.

The current order book represents the total annual production capacity for algae
oil in Houston in 2024, and the company has consequently taken a strategic
decision to increase the algae oil production capacity around fivefold. This
expansion will require limited investments as the company will utilize existing
infrastructure in Houston. Estimated time to completion is 12-18 months.

According to GOED Ingredient Market Report 2023, the total market for
algae-based omega-3 oil was USD 274 million (5,327 MT), of which dietary
supplements was USD 82 million (1,213 MT), in 2022. The average growth rate in
volume until 2025 is expected to be 10%.

For further information, please contact
Christopher Robin Vinter, VP IR & Corporate Finance
Mobile: +47 911 60 820
Email: Christopher.vinter@akerbiomarine.com

About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for consumer health and wellness as
well as animal nutrition. The company has a strong position in its industry and
is the world's leading supplier of krill, the natural, powerful and health
promoting source of nutrients from the pristine waters of Antarctica. Aker
BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available
at www.akerbiomarine.com.